Cover Image
市場調查報告書

高眼壓症:開發中產品分析

Ocular Hypertension - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 219790
出版日期 內容資訊 英文 137 Pages
訂單完成後即時交付
價格
Back to Top
高眼壓症:開發中產品分析 Ocular Hypertension - Pipeline Review, H2 2016
出版日期: 2016年08月31日 內容資訊: 英文 137 Pages
簡介

高眼壓症是眼睛內壓力(一般稱作眼壓)超過一般正常範圍(大約定義在21mm Hg以上)時所引起。症狀有眼睛疼痛或充血,虹視症,及頭痛等。原因包含了人種,家族病史,近視及糖尿病。治療有手術及使用特定的藥物。

本報告提供全球治療高眼壓症所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

高眼壓症概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

高眼壓症:企業開發中的的治療藥

高眼壓症:大學/機關研究中的治療藥

高眼壓症:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

高眼壓症:企業開發中的產品

高眼壓症:大學/機關研究中的產品

高眼壓症的治療藥開發作的企業

  • Aerie Pharmaceuticals, Inc.
  • Allergan Plc
  • Amakem NV
  • Bausch & Lomb Incorporated
  • Can-Fite BioPharma Ltd.
  • D. Western Therapeutics Institute, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Inotek Pharmaceuticals Corporation
  • Ironwood Pharmaceuticals, Inc.
  • 興和
  • Laboratoires Thea S.A.
  • Laboratorios Sophia S.A. de C.V.
  • Lee's Pharmaceutical Holdings Limited
  • Lexicon Pharmaceuticals, Inc.
  • NicOx S.A.
  • Ocular Therapeutix, Inc.
  • 大塚集團
  • pSivida Corp.
  • Sanofi
  • 參天製藥
  • 千壽製藥
  • Sylentis S.A.U.
  • ViSci Ltd.

高眼壓症:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

高眼壓症:暫停中的計劃

高眼壓症:開發中止的產品

高眼壓症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8410IDB

Summary

Global Markets Direct's, 'Ocular Hypertension - Pipeline Review, H2 2016', provides an overview of the Ocular Hypertension pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Ocular Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ocular Hypertension and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Ocular Hypertension
  • The report reviews pipeline therapeutics for Ocular Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Ocular Hypertension therapeutics and enlists all their major and minor projects
  • The report assesses Ocular Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Ocular Hypertension

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Ocular Hypertension
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Ocular Hypertension pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Ocular Hypertension Overview
  • Therapeutics Development
    • Pipeline Products for Ocular Hypertension - Overview
    • Pipeline Products for Ocular Hypertension - Comparative Analysis
  • Ocular Hypertension - Therapeutics under Development by Companies
  • Ocular Hypertension - Therapeutics under Investigation by Universities/Institutes
  • Ocular Hypertension - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Ocular Hypertension - Products under Development by Companies
  • Ocular Hypertension - Products under Investigation by Universities/Institutes
  • Ocular Hypertension - Companies Involved in Therapeutics Development
    • Aerie Pharmaceuticals, Inc.
    • Allergan Plc
    • Amakem NV
    • Bausch & Lomb Incorporated
    • Can-Fite BioPharma Ltd.
    • D. Western Therapeutics Institute, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Inotek Pharmaceuticals Corporation
    • Ironwood Pharmaceuticals, Inc.
    • Kowa Company, Ltd.
    • Laboratoires Thea S.A.
    • Laboratorios Sophia S.A. de C.V.
    • Lee's Pharmaceutical Holdings Limited
    • Lexicon Pharmaceuticals, Inc.
    • NicOx S.A.
    • Ocular Therapeutix, Inc.
    • Otsuka Holdings Co., Ltd.
    • pSivida Corp.
    • Sanofi
    • Santen Pharmaceutical Co., Ltd.
    • Senju Pharmaceutical Co., Ltd.
    • Sylentis S.A.U.
    • ViSci Ltd.
  • Ocular Hypertension - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (bimatoprost + brimonidine tartarate + timolol maleate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (bimatoprost + timolol maleate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (carteolol hydrochloride + latanoprost) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (latanoprost + netarsudil mesylate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (latanoprost + timolol maleate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (latanoprost + trabodenoson) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AMA-0076 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bamosiran - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bimatoprost - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bimatoprost SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DE-117 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Target Matrix Metalloproteinase 1 for Steroid Induced Glaucoma and Ocular Hypertension - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • H-1129 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IWP-953 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • latanoprost - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • latanoprost - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • latanoprost SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • latanoprost SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • latanoprost SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • latanoprostene bunod - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • levobetaxolol hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LX-7101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MGV-354 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NCX-1653 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NCX-470 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NCX-667 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • netarsudil mesylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OPA-6566 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • piclidenoson - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PRO-067 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RG-4929 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ripasudil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RO-5093151 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAR-366234 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Sepetaprost - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SNJ-1656 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • trabodenoson - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • travoprost SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • travoprost XR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Ocular Hypertension - Dormant Projects
  • Ocular Hypertension - Discontinued Products
  • Ocular Hypertension - Product Development Milestones
    • Featured News & Press Releases
      • Jun 16, 2016: Aerie Pharmaceuticals Completes Enrollment of Rocket 4 Phase 3 Clinical Trial of Rhopressa (netarsudil ophthalmic solution) 0.02%
      • May 05, 2016: Aerie Pharmaceuticals Completes Enrollment of Mercury 1 Phase 3 Registration Trial of Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%
      • Apr 27, 2016: Ocular Therapeutix Completes End-of-Phase 2 Review with FDA for OTX-TP (Sustained Release Travoprost) for Glaucoma and Ocular Hypertension
      • Apr 26, 2016: Inotek Pharmaceuticals Announces Poster Presentations on Trabodenoson at the ARVO 2016 Annual Meeting
      • Apr 11, 2016: Inotek Pharmaceuticals Announces the Journal of Ocular Pharmacology and Therapeutics has Published its Phase 2 Data for Trabodenoson in Patients with Glaucoma and Ocular Hypertension
      • Mar 28, 2016: Aerie Pharmaceuticals Initiates Second Phase 3 Registration Trial of Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%
      • Mar 17, 2016: Aerie Pharmaceuticals Reports Update on Positive Safety Results for Rhopressa QD (netarsudil ophthalmic solution) 0.02%
      • Mar 03, 2016: Aerie Pharmaceuticals Announces Availability on Its Website of Abstracts to be Presented at the American Glaucoma Society 26th Annual Meeting
      • Feb 22, 2016: Aerie Pharmaceuticals Announces Four New Abstracts to be Presented at the American Glaucoma Society 26th Annual Meeting Next Week
      • Feb 17, 2016: Aerie Pharmaceuticals Reports Positive Rhopressa QD (netarsudil ophthalmic solution) 0.02% 12 Month Interim Safety Results for Rocket 2
      • Feb 16, 2016: Ocular Therapeutix Announces Phase 3 Clinical Development Plan for OTX-TP, an Innovative Therapy for Glaucoma and Ocular Hypertension
      • Oct 22, 2015: Ocular Therapeutix Reports on Topline Results of Phase 2b Glaucoma Clinical Trial
      • Oct 01, 2015: New Drug Application for Carteolol Hydrochloride/ Latanoprost, a Novel Combined Ophthalmic Solution, Submitted in Japan for the Treatment of Glaucoma and Ocular Hypertension
      • Sep 24, 2015: Aerie Pharmaceuticals Initiates Fourth Phase 3 Clinical Trial of Rhopressa
      • Sep 21, 2015: Aerie Pharmaceuticals Initiates First Phase 3 Registration Trial of Roclatan
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Ocular Hypertension, H2 2016
  • Number of Products under Development for Ocular Hypertension - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Ocular Hypertension - Pipeline by Aerie Pharmaceuticals, Inc., H2 2016
  • Ocular Hypertension - Pipeline by Allergan Plc, H2 2016
  • Ocular Hypertension - Pipeline by Amakem NV, H2 2016
  • Ocular Hypertension - Pipeline by Bausch & Lomb Incorporated, H2 2016
  • Ocular Hypertension - Pipeline by Can-Fite BioPharma Ltd., H2 2016
  • Ocular Hypertension - Pipeline by D. Western Therapeutics Institute, Inc., H2 2016
  • Ocular Hypertension - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Ocular Hypertension - Pipeline by Inotek Pharmaceuticals Corporation, H2 2016
  • Ocular Hypertension - Pipeline by Ironwood Pharmaceuticals, Inc., H2 2016
  • Ocular Hypertension - Pipeline by Kowa Company, Ltd., H2 2016
  • Ocular Hypertension - Pipeline by Laboratoires Thea S.A., H2 2016
  • Ocular Hypertension - Pipeline by Laboratorios Sophia S.A. de C.V., H2 2016
  • Ocular Hypertension - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016
  • Ocular Hypertension - Pipeline by Lexicon Pharmaceuticals, Inc., H2 2016
  • Ocular Hypertension - Pipeline by NicOx S.A., H2 2016
  • Ocular Hypertension - Pipeline by Ocular Therapeutix, Inc., H2 2016
  • Ocular Hypertension - Pipeline by Otsuka Holdings Co., Ltd., H2 2016
  • Ocular Hypertension - Pipeline by pSivida Corp., H2 2016
  • Ocular Hypertension - Pipeline by Sanofi, H2 2016
  • Ocular Hypertension - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2016
  • Ocular Hypertension - Pipeline by Senju Pharmaceutical Co., Ltd., H2 2016
  • Ocular Hypertension - Pipeline by Sylentis S.A.U., H2 2016
  • Ocular Hypertension - Pipeline by ViSci Ltd., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Ocular Hypertension - Dormant Projects, H2 2016
  • Ocular Hypertension - Dormant Projects (Contd..1), H2 2016
  • Ocular Hypertension - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Ocular Hypertension, H2 2016
  • Number of Products under Development for Ocular Hypertension - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top